Heartbroken family calls for approval of life-saving cancer drug!
Huw Jones, a 33-year-old from Llanuwchllyn, tragically passed away from cholangiocarcinoma, a rare and aggressive cancer, leaving behind his partner, Cadi Rowlands, and their son, Idris. Diagnosed the day before their 20-week pregnancy scan, Huw fought bravely, joining a clinical trial for zanidatamab – a promising new drug that significantly improved his quality of life. “My condition improved a great deal,” he shared, emphasising reduced tumours and fewer side effects compared to traditional chemotherapy.
Despite personal success stories like Huw’s, the NHS watchdog has yet to approve zanidatamab for wider use. This has spurred an emotional plea from Cadi, backed by fellow patients like NHS surgeon Gareth Honeybone. Diagnosed at 27, Gareth experienced remarkable recovery after using the drug, getting him back to work and enjoying life again.
Supporters argue the drug not only extends life but significantly boosts its quality, offering hope where current treatments fall short. Cholangiocarcinoma is devastating, with only a quarter of patients surviving the first year post-diagnosis in England.
The charity AMMF reports that trials show encouraging results, with patients on zanidatamab living longer. They’re hopeful that further review will lead to its approval, bridging the care gap between those who can access clinical trials or private healthcare and those who cannot.
Let’s join these voices in urging for faster approval of zanidatamab, offering hope to many more families battling this disease.